Detalhe da pesquisa
1.
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
N Engl J Med
; 386(11): 1013-1025, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35294811
2.
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Haemophilia
; 27(6): 947-956, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378280
3.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482145
4.
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Adv Ther
; 41(6): 2267-2281, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38616241
5.
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
BJU Int
; 108(5): 679-86, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21156020
6.
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
Clin Colorectal Cancer
; 8(1): 29-37, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19203894
7.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
J Clin Oncol
; 34(32): 3921-3930, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601539
8.
Genome-wide linkage analysis of blood pressure under locus heterogeneity.
BMC Genet
; 4 Suppl 1: S78, 2003 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-14975146
9.
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
J Clin Oncol
; 28(9): 1527-33, 2010 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20159815
10.
The posterior probability of linkage allowing for linkage disequilibrium and a new estimate of disequilibrium between a trait and a marker.
Hum Hered
; 59(4): 210-9, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16015031